A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations

Background: In non-small-cell lung cancer (NSCLC), a pivotal factor in promoting cancer development is the rearrangement in the anaplastic lymphoma kinase ALK gene, resulting in elevated ALK protein expression. F1174C/L/V is the acquired secondary resistant mutation in ALK. Significant survival impr...

Full description

Bibliographic Details
Main Authors: Ambritha Balasundaram, George Priya C. Doss
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Molecular Biosciences
Subjects:
anaplastic lymphoma kinase
non-small-cell lung cancer
mutations
F1174C/L/V
lorlatinib
TPX-0131
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1306046/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2023.1306046/full

Similar Items